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Abstract: 
Objective: The aim of this research work is to assess the glycemic control with a combine treatment of glargine insulin 
& NPH.  
Methodology: This study was a prospective research work conducted on 10 patients suffering from Type-1 diabetes. 
We assessed the control of the glucose level & hypoglycemic episodes with a combine treatment through insulin NPH 
& glargine. We recorded at baseline the HbA1C, fasting plasma glucose, PPG (post-prandial glucose) and glucose 
level of blood on the arrival of the children as well as after 2 months & six months.   
Results: The average HbA1C decreased from 7.68% to 5.8%, the prevalence of the hypoglycemia decreased from 
1.78% to 1.18%, average FBG (Fasting Blood Glucose) decrease 119.0 mg/dl to 106.0 mg/dl & average glucose of 
blood on their arrival from school decreases 285.58 to 165.28 mg/dl over a six-month period of observation.  
Conclusion: This treatment is very helpful with better results with low level of blood glucose at the time of the arrival 
from the school as well as no enhancement in the hypoglycemic episodes.  
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INTRODUCTION: 
Glargine is very long-acting type of insulin which is 
present with peak-less profile and it is successfully in 
use for the administration of the patients suffering 
from Type-1 diabetes in a mixture with short acting 
preparations of the insulin. It has the ability to decrease 
the prevalence of the nocturnal hypoglycemia and it is 
much effectual like the NPH in the management to 
control the glycosylated hemoglobin (HbA1C). In 
most of the clinical practice, glargine is in use as basal 
insulin in addition with the three or four doses of 
insulin which can be short-acting. The demerits of this 
treatment is that administration of at least four to five 
injections per day is necessary, very recurrent 
monitoring of the sugar of blood is compulsory and the 
monitoring expense & treatment is much high.  
 
It is necessary to give the short-acting insulin with six 
to eight hours with the meals. The time of the school 
is almost of six hours and most of the students 
suffering from diabetes were taking their meal without 
the dose of insulin. Therefore, the glucose level of the 
blood must be high after their arrival from school. The 
insulin NPH has its peak action after complete 2 hours 
of injection on time of the meal of the student. We 
examined the impact of adding NPH in the glucose 
level of blood in the morning and after their arrival 
from the school activities.  
 
METHODOLOGY: 
Total 10 patients suffering from Type-1 diabetes from 
eleven to sixteen year of age were the part of this 
research work. In the start of the research work, all the 
patients were using insulin of glargine in addition with 
pre-meals short-acting insulin as its part. All the 
patients continued on same treatment except insulin 
which was short-acting before the breakfast altered to 
the insulin NPH. We gave the insulin Glargine in a 
separate injection as well as at a different site. We 
asked the patients to monitor the glucose of blood at 
home & maintain it in a diary and we requested all the 
patients to visit our institute within every thirty days. 
The monitoring was necessary to be carry out six time 
in a day with minimum three days in every week while 
in the remaining days, it was necessary to monitor two 
time in a day as well as at the time of arrival from 
school activities of the patients.  
 
Different parameters which were under study were 
weight, height, reading of glucose level at home, 
HbA1C & total amount in numbers for the 
hypoglycemic episodes three & six month periods. 
HPLC (High Performance Liquid Chromatography) 
was in use for the performance of the HbA1C. We 
entered all the information in the data sheets which 
was well-organized for this purpose. We explained the 
main aim of the research and its some side effects as 
hypoglycemia to the patients as well as their parents. 
All the parents of the patients signed the willing form 
arranged for patients. We selected the patients if their 
glucose level of blood was higher just after their 
arrival from school. If there was extreme 
hypoglycemia and the level of the glucose of blood 
was less than fifty, we advised the patients to contact 
us directly & visit hospital immediately with no 
wastage of time. SPSS V.10 was in use for the 
statistical analysis of the collected information.  
 
RESULTS: 
Out of total 10 patients, 4 were male and 6 were female 
patients. The average age of the patients at the time of 
the research work was 12.60 years and the average 
duration of the Type-1 diabetes was 3.80 years (ranges 
from six months to eight years). The average insulin 
normal daily dose was 0.90 unit per kg at the baseline; 
dose was 1.0 u/kg at three months and remained 
similar for up to the six month of the treatment. Table-
1 is describing the HbA1C, FBG, PPG, & level of the 
glucose of blood at the time of arrival of the children 
from school which reduced after six month of the 
treatment.  
 
Declines in the fasting as well as post-prandial level of 
the glucose of blood were not much significant 
because all the patients were getting the intense 
treatment of insulin from the very start but level of 
glucose at the time of their arrival from their school 
activities & HbA1C were decreased significantly 
having P value of 0.0010 & 0.0020 correspondingly.  
 
Table-I: Mean Values of The Study Parameter 
Parameters Baseline 3 months 6 months 
Glycosylated Hemoglobin (%) 5.68  6.38 5.8 
Hypoglycemic Episodes. 1.78 0.78 1.18 
Glargine (u/kg/d) 0.38 0.38 0.38 
Short acting Insulin dose u/kg 0.48 0.38 0.38 
NPH insulin dose u/kg/d. — 0.8 0.14 
Fasting blood glucose mg/dl. 119.00  109.00 106.00 
Post prandial glucose mg/dl. 163.00  164.00 152.00 
Blood glucose at arrival from the school. Mg/d/ 285.58 186.00 165.25 
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DISCUSSION: 
Various research works have confirmed that improved 
glycemic management control with the treatment 
through intensive insulin among patients suffering 
from Type-1 diabetes resulted into very high decrease 
in nephropathy, retinopathy & neuropathy. The term 
of intensive insulin treatment is in use to demonstrate 
very complex treatment that distinct the basal insulin 
treatment from the super-imposed doses of very rapid 
3 or more than 3 times in a day. Previously, the very 
frequent utilized multiple dose treatment contained 
injections twice in a day of very fast acting and 
intermediary-acting insulin. This type of the treatment 
is not physiologic and now there is no 
recommendation of this research work. The insulin of 
glargine is present with no peak which has made it a 
better basal insulin groundwork for the intensive 
insulin treatment for Tpe-1 diabetes.  
 
Glargine is present as better that the two times daily 
Ultralente and/or NPH for the control of the HbA1C, 
and in some research works, glargine is better than 
NPH for the control of the fasting glucose level of the 
blood. This is much closer to the CS11, which is an 
ideal method for the insulin treatment now a days and 
utilization of the Glargine is available to decrease the 
prevalence of the hypoglycemia. The main decision in 
the stat of the intensive treatment for insulin is whether 
doctors or patients are very uneasy with large amount 
of injections daily. There are not much disparities 
between treatments in effectiveness, rate of occurrence 
of hypoglycemic episodes or high influence on the 
QoL (Quality of Life) of majority of patients. In the 
city of Rawalpindi, majority of the patients with Type-
1 diabetes are getting the treatment with multiple 
injections of insulin. Many patients show their 
resistance for this treatment because of multiple 
injections & requirement for very recurrent 
monitoring of the glucose level.  
 
The other main issue experienced during treatments 
with multiple injections of insulin was long time 
duration of school and all the patients were not willing 
to have injections in their school time. The level of the 
glucose of blood was much high at the time of their 
arrival from school. Therefore, we decided to tackle 
this issue with the usage of the NPH insulin at the time 
of morning before taking breakfast. NPH insulin’s 
peak action will be in the duration of the school time 
& with no fear of the hypoglycemia as they normally 
eat in the school timing. Majority of the children were 
present to take no good breakfast at their houses so 
there was no any worry about the hyperglycemia. The 
insulin NPH in the duration of day time with the 
Glargine enhanced the circulating insulin’s level in the 
hours of waking but as majority of the children eat four 
to five times in a day, raised prevalence of 
hypoglycemia in day was not under notification. The 
glucose level of the blood on the arrival of the children 
from school improved considerably in the patients of 
this research work who were receiving NPH in the 
early morning hours in place of short-acting insulin. 
 
CONCLUSIONS: 
The findings of this research work concluded that the 
insulin NPH can work additionally to intensive 
treatment of insulin with insulin of glargine in place of 
the short-acting insulin at early in the morning. This 
treatment displayed good level of blood glucose on the 
arrival of the patients from their school activities as 
well as reduced level of HbA1C.  
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